Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Epizyme, Inc.
Report date August 12, 2022 · Filed August 16, 2022
Section 16 reporting ended · disclosed 2022-08-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-08-12 · Disposition to issuer · Disposed 20,341 · Balance 25,696 F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Row 2 · 2022-08-12 · Disposition to issuer · Disposed 25,696 · Balance 0 F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price.
F2: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding.
HUMANA INC
Report date April 01, 2019 · Filed April 01, 2019
Section 16 reporting ended · disclosed 2019-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Humana CommonSEC Table I · non-derivative | Direct | 10,791 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,791 |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $167.81 · Expires 2023-02-18 | Direct | 7,084 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 7,084 F1: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $217.42 · Expires 2024-03-08 | Direct | 15,997 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15,997 F2: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 03/08/2017. 10,998 options vesting in three annual increments, and 4,999 options fully vest three years from the date of grant. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $268.47 · Expires 2025-02-19 | Direct | 4,415 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 4,415 F3: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/19/18, vesting in three increments from 02/19/19 to 02/19/21. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,993 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,993 F4: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F5: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 683 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 683 F4: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F6: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20. |
Filing footnotes · ownership attribution and instrument terms
F1: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19.
F2: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 03/08/2017. 10,998 options vesting in three annual increments, and 4,999 options fully vest three years from the date of grant.
F3: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/19/18, vesting in three increments from 02/19/19 to 02/19/21.
F4: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3).
F5: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant.
F6: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2022 Filed Aug 16, 2022 18:58 UTC | Epizyme, Inc. EPZM · Entity 12703 | Disposition to issuerCommon Stock, par value $0.0001 | 25,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028868 · doc4.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. F2 · price: Reflects disposition of restricted stock units ("RSUs") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding. Read SEC document |
| August 12, 2022 Filed Aug 16, 2022 18:58 UTC | Epizyme, Inc. EPZM · Entity 12703 | Disposition to issuerCommon Stock, par value $0.0001 | 20,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-028868 · doc4.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,696 F1 · shares: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. F1 · price: Reflects disposition of shares of common stock of the Issuer ("Shares") in connection with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the "Effective Time"), each Share held by the Reporting Person was converted into the Offer Price. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 17:06 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 8,928 | $1.47 | $13,124.16 |
DisclosureSEC source: 0000899243-22-025017 · doc4.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,037 F1 · shares: The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $13,125 for Board services for the second fiscal quarter of 2022. The shares were issued on the last day of the second fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:20 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 41,006 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0000899243-22-018808 · doc4.xml · derivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,006 Underlying: Common Stock · 41,006 shares Expires 2032-05-16 F2 · derivative.exercise_date: This option was granted on May 17, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full. Read SEC document |
| May 17, 2022 Filed May 19, 2022 16:20 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 8,994 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018808 · doc4.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,109 F1 · shares: Consists of shares of Common Stock issuable under 8,994 restricted stock units ("RSUs") granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:31 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 11,413 | $1.15 | $13,124.95 |
DisclosureSEC source: 0000899243-22-013155 · doc4.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,115 F1 · shares: The shares were issued to the Reporting Person pursuant to his election under the Issuer's director compensation program to receive such shares in lieu of cash fees of $13,125 for Board services for the first fiscal quarter of 2022. The shares were issued on the last day of the first fiscal quarter and the number of shares was calculated by dividing the cash fees to be paid for the quarter by the closing price of the Issuer's common stock on the last trading day of the quarter. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 08:22 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantStock Option (Right to Buy) · Derivative | 83,298 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0000899243-21-045212 · doc4.xml · derivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,298 Underlying: Common Stock · 83,298 shares Expires 2031-11-15 F2 · shares: The number of shares of the Common Stock issuable upon exercise of the Option (as defined below) and underlying the RSUs granted to Dr. Beveridge accounts for adjustment based on the terms of the Issuer's non-employee director compensation program, which provides that the aggregate number of shares of Common Stock issuable upon exercise of the initial option grant and underlying the initial RSU grant to each new director shall in no event exceed a total of 100,000 shares. F3 · derivative.exercise_date: This option (the "Option") was granted on November 16, 2021 pursuant to the Issuer's 2013 Stock Incentive Plan with respect to 83,298 shares of Common Stock, with 33% vesting on November 16, 2022 and the remaining shares underlying the Option vesting in 24 substantially equal monthly installments thereafter, subject to continued service as a director. In the event of a change in control of the Issuer, the Option will vest in full. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 08:22 UTC | Epizyme, Inc. EPZM · Entity 12703 | GrantCommon Stock, par value $0.0001 | 16,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045212 · doc4.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,702 F1 · shares: Consists of shares of Common Stock issuable under 16,702 restricted stock units ("RSUs") granted pursuant to the Issuer's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal annual installments over three years from the grant date, with the first installment vesting on November 16, 2022, subject to continued service as a director. In the event of a change in control of the Issuer, the RSUs will vest in full. F2 · balance_after: The number of shares of the Common Stock issuable upon exercise of the Option (as defined below) and underlying the RSUs granted to Dr. Beveridge accounts for adjustment based on the terms of the Issuer's non-employee director compensation program, which provides that the aggregate number of shares of Common Stock issuable upon exercise of the initial option grant and underlying the initial RSU grant to each new director shall in no event exceed a total of 100,000 shares. Read SEC document |
| February 20, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · nonDerivative · entry 5 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,791 F9 · price: Transaction representing a gift/chartiable donation effective February 20, 2019 in which no value was received in return. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionOptions · Derivative | 7,680 | $0.00 Strike: $167.81 | $0.00 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · derivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,084 Underlying: Humana Common · 7,680 shares Expires 2023-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19. F1 · derivative.exercise_date: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/16, vesting in three increments from 02/18/17 to 02/18/19. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 8,278 | $307.16 | $2,542,653.10 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · nonDerivative · entry 4 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,891 F8 · price: 1,193 shares sold at price of $307.1334. 7,085 shares sold at prices ranging from $306.56 to $307.1579. Price reported is weighted average sales price. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 7,085 | $167.81 | $1,188,898.43 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · nonDerivative · entry 3 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 325 | $307.22 | $99,844.88 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,084 F7 · price: Shares swapped for payment of purchase price on stock option exercise using fair market value on February 15, 2019 pursuant to Humana Inc's 2011 Stock Incentive Plan. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 15:24 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 595 | $167.81 | $99,843.98 |
DisclosureSEC source: 0000049071-19-000018 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionRestricted Stock Units · Derivative | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · derivative · entry 12 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 683 Underlying: Humana Common · 341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F4 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F7 · derivative.exercise_date: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20. F7 · derivative.expiration_date: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionRestricted Stock Units · Derivative | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · derivative · entry 11 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,993 Underlying: Humana Common · 843 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F4 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F6 · derivative.exercise_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant. F6 · derivative.expiration_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionRestricted Stock Units · Derivative | 1,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · derivative · entry 10 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Humana Common · 1,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F4 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F5 · derivative.exercise_date: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18. F5 · derivative.expiration_date: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 163 | $304.05 | $49,559.34 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,814 Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 5 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 401 | $304.05 | $121,922.05 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 4 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,636 Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 3 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 520 | $304.05 | $158,103.40 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,194 Read SEC document |
| December 15, 2018 Filed Dec 18, 2018 16:48 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 1,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000142 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 14:47 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 4,622 | $341.06 | $1,576,395.50 |
DisclosureSEC source: 0000049071-18-000126 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,621 F8 · price: Shares sold at prices ranging from $341.0018 to $341.2915. Price reported is weighted average sales price. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionOptions · Derivative | 14,913 | $0.00 Strike: $164.65 | $0.00 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · derivative · entry 8 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Humana Common · 14,913 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18. F2 · derivative.exercise_date: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/24/15, vesting in three increments from 02/24/16 to 02/24/18. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionOptions · Derivative | 1,291 | $0.00 Strike: $81.80 | $0.00 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · derivative · entry 7 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Humana Common · 1,291 shares Expires 2020-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 06/17/13, vesting in three increments from 06/17/14 to 06/17/16. F1 · derivative.exercise_date: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 06/17/13, vesting in three increments from 06/17/14 to 06/17/16. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 14,306 | $324.25 | $4,638,757.70 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,243 F11 · price: Shares sold at prices ranging from $323.49 to $325.08. Price reported is weighted average sales price. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 14,306 | $164.65 | $2,355,411.37 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 5 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 310 | $322.73 | $100,044.75 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 4 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,243 F10 · price: Shares swapped for payment of purchase price on stock option exercise using fair market value on August 3, 2018 pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 607 | $164.65 | $99,939.52 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 3 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 328 | $322.73 | $105,853.80 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,946 F10 · price: Shares swapped for payment of purchase price on stock option exercise using fair market value on August 3, 2018 pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:01 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 1,291 | $81.80 | $105,597.35 |
DisclosureSEC source: 0000049071-18-000105 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2018 Filed May 18, 2018 17:52 UTC | HUMANA INC HUM · Entity 1429 | GiftHumana Common | 104 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000070 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,983 F10 · shares: This transaction represents a gift/charitable donation effective May 18, 2018. This is not a market transaction and no value was received in return for the shares. Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 23:31 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 1,048 | $269.31 | $282,236.88 |
DisclosureSEC source: 0000049071-18-000038 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,087 Read SEC document |
| February 24, 2018 Filed Feb 27, 2018 23:31 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 3,174 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000038 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · shares: Includes Performance Stock Units that vested on 2/24/2018. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 19:33 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 1,024 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-18-000018 · edgar.xml · derivative · entry 9 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024 Underlying: Humana Common · 1,024 shares Expires not disclosed F6 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F6 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F9 · derivative.exercise_date: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20. F9 · derivative.expiration_date: Restricted stock units granted to reporting person on 02/19/18, 33% of the award is vesting on 12/15/18, 12/15/19, and 12/15/20. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 19:33 UTC | HUMANA INC HUM · Entity 1429 | GrantOptions · Derivative | 4,415 | $0.00 Strike: $268.47 | $0.00 |
DisclosureSEC source: 0000049071-18-000018 · edgar.xml · derivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,415 Underlying: Humana Common · 4,415 shares Expires 2025-02-19 F5 · security: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/19/18, vesting in three increments from 02/19/19 to 02/19/21. F5 · derivative.exercise_date: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/19/18, vesting in three increments from 02/19/19 to 02/19/21. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:13 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionRestricted Stock Units · Derivative | 842 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000185 · edgar.xml · derivative · entry 8 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,836 Underlying: Humana Common · 842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F5 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F7 · derivative.exercise_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant. F7 · derivative.expiration_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments on 12/15/17, 12/15/18, and 12/15/19. 1,149 shares fully vest three years from the date of grant. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:13 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionRestricted Stock Units · Derivative | 1,093 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000185 · edgar.xml · derivative · entry 7 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,093 Underlying: Humana Common · 1,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F5 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F6 · derivative.exercise_date: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18. F6 · derivative.expiration_date: Restricted stock units granted to reporting person on 02/18/16, 33% of the award is vesting on 12/15/16, 12/15/17, and 12/15/18. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:13 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 977 | $253.62 | $247,786.74 |
DisclosureSEC source: 0000049071-17-000185 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,961 Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 17:13 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 1,935 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000185 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionOptions · Derivative | 15,086 | $0.00 Strike: $102.16 | $0.00 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · derivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Humana Common · 15,086 shares Expires 2021-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/14, vesting in three increments from 02/18/15 to 02/18/17. F2 · derivative.exercise_date: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 02/18/14, vesting in three increments from 02/18/15 to 02/18/17. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionOptions · Derivative | 14,290 | $0.00 Strike: $81.80 | $0.00 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · derivative · entry 5 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291 Underlying: Humana Common · 14,290 shares Expires 2020-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 06/17/13, vesting in three increments from 06/17/14 to 06/17/16. F1 · derivative.exercise_date: Right to buy pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 06/17/13, vesting in three increments from 06/17/14 to 06/17/16. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Tax withholdingHumana Common | 1,281 | $229.77 | $294,328.97 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · nonDerivative · entry 4 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,003 F10 · price: Shares swapped for payment of purchase price on incentive stock option exercises using fair market value on May 11, 2017, pursuant to Humana Inc.'s 2011 Stock Incentive Plan. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 26,023 | $231.99 | $6,037,172.06 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · nonDerivative · entry 3 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Shares sold at prices ranging from $231.88 to $232.10. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 15,086 | $102.16 | $1,541,110.33 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · nonDerivative · entry 2 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:45 UTC | HUMANA INC HUM · Entity 1429 | Exercise / conversionHumana Common | 14,290 | $81.80 | $1,168,850.55 |
DisclosureSEC source: 0000049071-17-000117 · edgar.xml · nonDerivative · entry 1 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:58 UTC | HUMANA INC HUM · Entity 1429 | GrantRestricted Stock Units · Derivative | 3,678 | $0.00 | $0.00 |
DisclosureSEC source: 0000049071-17-000069 · edgar.xml · derivative · entry 8 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,678 Underlying: Humana Common · 3,678 shares Expires not disclosed F6 · security: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F6 · derivative.exercise_price: Right to receive one share per restricted stock unit pursuant to the Company's 2011 Stock Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Humana Inc. common stock, exempt under Rule 16b-3(d)(1) & (3). F8 · derivative.exercise_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments, and 1,149 shares fully vest three years from the date of grant. F8 · derivative.expiration_date: Restricted stock units granted to reporting person on 03/08/2017, 2,529 shares vesting in three annual increments, and 1,149 shares fully vest three years from the date of grant. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:58 UTC | HUMANA INC HUM · Entity 1429 | GrantOptions · Derivative | 15,997 | $0.00 Strike: $217.42 | $0.00 |
DisclosureSEC source: 0000049071-17-000069 · edgar.xml · derivative · entry 6 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,997 Underlying: Humana Common · 15,997 shares Expires 2024-03-08 F4 · security: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 03/08/2017. 10,998 options vesting in three annual increments, and 4,999 options fully vest three years from the date of grant. F4 · derivative.exercise_date: Right to buy pursuant to Company's 2011 Stock Incentive Plan. Incentive and Non-Qualified stock options granted to reporting person on 03/08/2017. 10,998 options vesting in three annual increments, and 4,999 options fully vest three years from the date of grant. Read SEC document |
| February 22, 2017 Filed Feb 22, 2017 23:47 UTC | HUMANA INC HUM · Entity 1429 | SaleHumana Common | 4,832 | $205.73 | $994,089.78 |
DisclosureSEC source: 0000049071-17-000030 · edgar.xml · nonDerivative · entry 3 BEVERIDGE, ROY A · CIK 0001579300 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,931 F9 · price: Shares sold at a prices ranging from $205.7076 to $205.77. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.